CPA
SYRE icon

Capital Performance Advisors’s Spyre Therapeutics SYRE Stock Holding History

Capital Performance Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-46
Closed -$1.35K – 2398
2024
Q3 		$1.35K Buy
+46
New +$1.28K ﹤0.01% 1761

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Capital Performance Advisors's SYRE Position: Q4 2024 in Review

Capital Performance Advisors sold out of Spyre Therapeutics (SYRE) in Q4 2024, closing a stake of 46 shares — an estimated $1.35K sold.

Capital Performance Advisors first reported a position in SYRE in Q3 2024 and held it in 1 quarter. The position peaked at $1.35K in Q3 2024. 131 funds tracked by Wall St. Rank hold SYRE as of Q4 2024.

  • Capital Performance Advisors reported no remaining Spyre Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 46 Spyre Therapeutics shares in Q4 2024, an estimated $1.35K.
  • Capital Performance Advisors first reported a position in Spyre Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Spyre Therapeutics position peaked at $1.35K in Q3 2024.
  • 131 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.